ADC Therapeutics SA, developer of antibody-drug conjugates (ADCs), has appointed Jennifer Herron to the newly created position of chief commercial officer as the company plans for a US regulatory submission of its lead product for diffuse large B cell lymphoma. Ms Herron was most recently chief commercial officer at ImmunoGen Inc where she guided planning for an ADC for ovarian cancer. Prior to this, she was head of global commercial affairs at the US division of MorphoSys AG. Ms Herron holds an MBA from Georgetown University and a BA in biology and economics from Lehigh University, both in the US.
ADC Therapeutics announced the appointment on 5 November 2019
